Literature DB >> 10764165

Variation in the frequency of Epstein-Barr virus-associated Hodgkin's disease with age.

K J Flavell1, J P Biddulph, C M Constandinou, D Lowe, K Scott, J Crocker, L S Young, P G Murray.   

Abstract

A number of studies in developed countries have reported variation in the frequency of Epstein-Barr virus (EBV)-associated Hodgkin's disease (HD) with age. A 'three disease' model for HD that incorporates the EBV association, histological subtype of HD and age has recently been proposed. In this model, Hodgkin's disease of childhood and older adults is commonly EBV-associated and of mixed cellularity type, whereas young adult HD is generally not EBV-associated and is usually characterised by nodular sclerosis disease. A case series of HD diagnosed in the West Midlands between 1981 and 1997, inclusive, was used to investigate the applicability of the 'three disease' model. In situ hybridisation for the EBV early RNAs (EBERs) was used to determine the presence of EBV in the malignant Hodgkin/Reed-Sternberg cells. In contrast to the 'three disease' model, nodular sclerosis was the predominant subtype in each of the age groups within the case series. In addition, overall there was little variation in EBV-positive rates across the age ranges examined. However, when females were analysed separately, older women (45+ years) were significantly more likely to have EBV-positive disease than their younger counterparts (<45 years). In summary our results do not generally support the 'three disease' model.

Entities:  

Mesh:

Year:  2000        PMID: 10764165     DOI: 10.1038/sj.leu.2401724

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

Review 1.  Hodgkin's disease and the Epstein-Barr virus.

Authors:  K J Flavell; P G Murray
Journal:  Mol Pathol       Date:  2000-10

Review 2.  An Update on the Pathology and Molecular Features of Hodgkin Lymphoma.

Authors:  Akira Satou; Taishi Takahara; Shigeo Nakamura
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

3.  Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations.

Authors:  Sally L Glaser; Margaret L Gulley; Christina A Clarke; Theresa H Keegan; Ellen T Chang; Sarah J Shema; Fiona E Craig; Joseph A Digiuseppe; Ronald F Dorfman; Risa B Mann; Hoda Anton-Culver; Richard F Ambinder
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

4.  Cancers in Australia in 2010 attributable to modifiable factors: introduction and overview.

Authors:  David C Whiteman; Penelope M Webb; Adele C Green; Rachel E Neale; Lin Fritschi; Christopher J Bain; D Max Parkin; Louise F Wilson; Catherine M Olsen; Christina M Nagle; Nirmala Pandeya; Susan J Jordan; Annika Antonsson; Bradley J Kendall; Maria Celia B Hughes; Torukiri I Ibiebele; Kyoko Miura; Susan Peters; Renee N Carey
Journal:  Aust N Z J Public Health       Date:  2015-10       Impact factor: 2.939

5.  Cancers in Australia in 2010 attributable to infectious agents.

Authors:  Annika Antonsson; Louise F Wilson; Bradley J Kendall; Christopher J Bain; David C Whiteman; Rachel E Neale
Journal:  Aust N Z J Public Health       Date:  2015-10       Impact factor: 2.939

6.  CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function.

Authors:  Keyur Thakar; Aileen Novero; Arundhati Das; Adriana Lisinschi; Bella Mehta; Tauseef Ahmed; Delong Liu
Journal:  Biomark Res       Date:  2014-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.